CN110092727B - Synthetic method of laquinimod intermediate 2-amino-6-chlorobenzoic acid - Google Patents
Synthetic method of laquinimod intermediate 2-amino-6-chlorobenzoic acid Download PDFInfo
- Publication number
- CN110092727B CN110092727B CN201910331199.9A CN201910331199A CN110092727B CN 110092727 B CN110092727 B CN 110092727B CN 201910331199 A CN201910331199 A CN 201910331199A CN 110092727 B CN110092727 B CN 110092727B
- Authority
- CN
- China
- Prior art keywords
- solvent
- mixture
- chloro
- controlling
- methylaniline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- SZCPTRGBOVXVCA-UHFFFAOYSA-N 2-amino-6-chlorobenzoic acid Chemical compound NC1=CC=CC(Cl)=C1C(O)=O SZCPTRGBOVXVCA-UHFFFAOYSA-N 0.000 title claims abstract description 20
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 229960004577 laquinimod Drugs 0.000 title claims abstract description 17
- 238000010189 synthetic method Methods 0.000 title claims abstract description 7
- ZUVPLKVDZNDZCM-UHFFFAOYSA-N 3-chloro-2-methylaniline Chemical compound CC1=C(N)C=CC=C1Cl ZUVPLKVDZNDZCM-UHFFFAOYSA-N 0.000 claims abstract description 64
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 238000006243 chemical reaction Methods 0.000 claims abstract description 53
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000002904 solvent Substances 0.000 claims abstract description 36
- 239000007800 oxidant agent Substances 0.000 claims abstract description 29
- 230000001590 oxidative effect Effects 0.000 claims abstract description 27
- 238000002156 mixing Methods 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 13
- 238000001816 cooling Methods 0.000 claims abstract description 12
- 239000003223 protective agent Substances 0.000 claims abstract description 9
- 239000002274 desiccant Substances 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 6
- 238000001704 evaporation Methods 0.000 claims abstract description 6
- 239000012074 organic phase Substances 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 238000005406 washing Methods 0.000 claims abstract description 6
- 230000001681 protective effect Effects 0.000 claims abstract description 5
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 claims description 44
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 claims description 30
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical group CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 14
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 11
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- 229910052786 argon Inorganic materials 0.000 claims description 7
- 239000007789 gas Substances 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 5
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical group [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 abstract description 7
- 230000001276 controlling effect Effects 0.000 description 17
- 239000000047 product Substances 0.000 description 14
- 238000007254 oxidation reaction Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JYHOMEFOTKWQPN-UHFFFAOYSA-N 2-chloro-6-nitrobenzoic acid Chemical compound OC(=O)C1=C(Cl)C=CC=C1[N+]([O-])=O JYHOMEFOTKWQPN-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- -1 manganese dioxide-potassium dichromate Chemical compound 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
- C07C227/20—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters by hydrolysis of N-acylated amino-acids or derivatives thereof, e.g. hydrolysis of carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
The invention discloses a synthetic method of laquinimod intermediate 2-amino-6-chlorobenzoic acid, which is characterized in that 3-chloro-2-methylaniline reacts under the action of a protective agent and an oxidant to obtain 2-amino-6-chlorobenzoic acid, and the reaction process comprises the following steps: 1) uniformly mixing 3-chloro-2-methylaniline, a protective agent and a solvent S1, and stirring and reacting at 40-50 ℃ for 1-2 h to obtain a mixture I; 2) uniformly mixing an oxidant, water and a solvent S2, introducing protective gas, controlling the reaction temperature to be 145-155 ℃ and the reaction pressure to be 5-7 atmospheres to obtain a mixture II, dropwise adding the mixture I into the mixture II, controlling the dropwise adding time to be 50-70 min, then controlling the temperature to be 160-175 ℃ and the reaction pressure to be 8-10 atmospheres, and continuously reacting for 6-8 h and cooling to obtain a mixture III; 3) adding hydrochloric acid and a solvent S3 into the mixture III, controlling the reaction temperature to be 75-90 ℃, controlling the reaction pressure to be normal pressure, reacting for 0.5-1 h, and cooling to obtain a mixture IV; 4) adding a solvent S4 into the mixture IV, standing for layering, washing an organic phase with water, drying a drying agent, and concentrating and evaporating to remove the solvent to obtain a product. The method has low cost of raw materials and high yield.
Description
Technical Field
The invention belongs to the field of pharmacy, and particularly relates to a synthetic method of a laquinimod intermediate 2-amino-6-chlorobenzoic acid.
Background
Laquinimod (Laquinimod) chemically known as 5-chloro-1, 2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide is a structural analogue of roquinacre (linoamine). Laquinimod is an immunoregulatory drug developed by Teva pharmaceutical company and Active biotechnology, is mainly used for treating multiple sclerosis, and is convenient to use and weak in adverse reaction compared with other drugs for treating multiple sclerosis such as interferon and mitoxantrone. Laquinimod can completely inhibit murine chronic experimental autoimmune encephalomyelitis (chaae) by eliminating leukocyte infiltration of the central nervous system, reduce inflammation, demyelination and axonal injury in an EAE (experimental autoimmune encephalomyelitis) animal model, can be anti-inflammatory and can protect nerves, has stronger inhibition effect than that of the laquinimod, and has 20 times of the immunosuppression effect of the laquinimod compared with the exposed dosage directly.
In the prior art, laquinimod (compound 5) is often synthesized using the following route.
2-amino-6-chlorobenzoic acid is a raw material and an intermediate for synthesizing laquinimod. Invention patent
CN201610292940 provides a method for synthesizing 2-amino-6-chlorobenzoic acid, which comprises the steps of taking 2-chloro-6-nitrobenzoic acid as a raw material, reducing nitro to obtain 2-amino-6-chlorobenzoic acid:
the method has high cost of raw materials, and substances with strong irritation, such as cerium chloride, are used in the process, so that the method is not beneficial to safe operation.
Disclosure of Invention
The invention aims to provide a synthetic method of a laquinimod intermediate 2-amino-6-chlorobenzoic acid, which has the advantages of low cost of raw materials, high yield and avoidance of use of irritant substances.
In order to achieve the purpose, the invention adopts the following technical scheme:
the synthetic method of the laquinimod intermediate 2-amino-6-chlorobenzoic acid is characterized in that 3-chloro-2-methylaniline reacts under the action of a protective agent and an oxidant to obtain the 2-amino-6-chlorobenzoic acid, and the reaction process comprises the following steps:
1) uniformly mixing 3-chloro-2-methylaniline, a protective agent and a solvent S1, and stirring and reacting at 40-50 ℃ for 1-2 h to obtain a mixture I;
2) uniformly mixing an oxidant, water and a solvent S2, introducing protective gas, controlling the reaction temperature to be 145-155 ℃ and the reaction pressure to be 5-7 atmospheres to obtain a mixture II, dropwise adding the mixture I into the mixture II, controlling the dropwise adding time to be 50-70 min, then controlling the temperature to be 160-175 ℃ and the reaction pressure to be 8-10 atmospheres, and continuously reacting for 6-8 h and cooling to obtain a mixture III;
3) adding hydrochloric acid and a solvent S3 into the mixture III, controlling the reaction temperature to be 75-90 ℃, controlling the reaction pressure to be normal pressure, reacting for 0.5-1 h, and cooling to obtain a mixture IV;
4) adding a solvent S4 into the mixture IV, standing for layering, washing an organic phase with water, drying a drying agent, and concentrating and evaporating to remove the solvent to obtain a product.
The preparation method of the oxidant comprises the following steps: uniformly mixing ferric trichloride, manganese dioxide and potassium dichromate, and activating at 150-180 ℃ for 30-60 min under the condition of isolating oxygen to obtain the product; the molar ratio of the ferric trichloride to the manganese dioxide to the potassium dichromate is 1 (8-10) to 16-18; the manganese dioxide is freshly prepared.
The protective agent is di-tert-butyl dicarbonate, the solvent S1 is benzene, chlorobenzene or fluorobenzene, the solvent S2 is tetrahydrofuran, the solvent S3 is dioxane, the solvent S4 is toluene or chloroform, the protective gas is nitrogen or argon, and the drying agent is anhydrous sodium sulfate or anhydrous magnesium sulfate.
The molar ratio of the 3-chloro-2-methylaniline to the protective agent is 1 (1.2-1.4), the molar ratio of the 3-chloro-2-methylaniline to the manganese dioxide in the oxidant is 1 (2.1-3.2), and the dosage ratio of the 3-chloro-2-methylaniline to the solvent S1, the solvent S2 and the water is 1g, (3-5) mL, (4-6) mL, (0.5-1.2) g.
The concentration of the hydrochloric acid is 20% by mass; the molar ratio of the 3-chloro-2-methylaniline to the hydrogen chloride in the hydrochloric acid is 1 (1.6-2.2); the volume ratio of the hydrochloric acid to the solvent S3 is 1 (1.5-3); the volume ratio of the solvent S4 to the solvent S3 is 1 (2-4).
The reaction principle of the invention is shown as the following formula:
in the prior literature, the method for methyl oxidation of aromatic ring into carboxyl is mostly obtained by direct oxidation with strong oxidant. The reaction process of the invention is a process for oxidizing methyl on a benzene ring of 3-chloro-2-methylaniline into carboxyl. Since amino groups which are easily oxidized exist in the structure of the raw material 3-chloro-2-methylaniline, it is necessary to pre-protect the amino groups and to adjust the oxidizing property of the oxidizing agent. The invention adopts ferric trichloride, newly-prepared manganese dioxide and potassium dichromate which are mixed according to a proportion as an oxidant, and the oxidant has moderate oxidizability under the proportion: the reaction condition of independent potassium dichromate plus acidity is adopted, so that the oxidizing property is strong, and even protected amino groups can be oxidized; the reaction condition of newly prepared manganese dioxide + acidity is adopted, the oxidability is weak, and incomplete oxidation products such as aldehyde groups and the like can be generated from methyl. Meanwhile, the oxidizability of the metal oxidizer is often weak in alkalinity and strong in acidity, and is enhanced with the enhancement of the acidity. Therefore, proper acidity is also important for the regulation of oxidation. Ferric trichloride is added into the system, and under the condition of the existence of a proper amount of water, the system can show proper weak acidity, the oxidation can be regulated, and the generation of peroxidation and incomplete oxidation products can be reduced or avoided. The method adopts a mode of dropwise adding the reactant solution into the oxidant solution, can quickly finish the oxidation reaction as much as possible, and avoids incomplete oxidation caused by overlarge concentration of the reactant and relatively small concentration of the oxidant. And after the oxidation reaction is finished, carrying out deprotection on amino by adopting an acid system to finally obtain the 2-amino-6-chlorobenzoic acid.
Compared with the prior art, the invention has the advantages that:
1. 3-chloro-2-methylaniline is used as a raw material, so that the cost is low;
2. the reaction yield is high;
3. less by-products.
Detailed Description
The present invention will be further described with reference to the following examples.
Example 1
The synthesis method of 2-amino-6-chlorobenzoic acid comprises the following steps:
1) uniformly mixing 3-chloro-2-methylaniline, di-tert-butyl dicarbonate and benzene, and stirring at 46 ℃ to react for 1.5h to obtain a mixture I;
2) uniformly mixing an oxidant, water and tetrahydrofuran, introducing argon, controlling the reaction temperature to be 150 ℃ and the reaction pressure to be 6 atmospheres to obtain a mixture II, dropwise adding the mixture I into the mixture II, controlling the dropwise adding time to be 65min, then controlling the temperature to be 171 ℃ and the reaction pressure to be 9 atmospheres, continuously reacting for 7.5 hours, and cooling to obtain a mixture III;
3) adding hydrochloric acid and dioxane with the mass fraction of 20% into the mixture III, controlling the reaction temperature to be 85 ℃, the reaction pressure to be normal pressure, reacting for 45min, and cooling to obtain a mixture IV;
4) and adding chloroform into the mixture IV, standing for layering, washing an organic phase with water, drying with anhydrous sodium sulfate, and concentrating and evaporating to remove the solvent by using a rotary evaporator to obtain a product. The molar yield was 99.1% and the GC purity 98.5%.
In the above step, the method for preparing the oxidizing agent: uniformly mixing ferric trichloride, newly-prepared manganese dioxide and potassium dichromate, and activating for 50min at 170 ℃ by using a vacuum drying oven under the protection of argon gas to obtain the product; the molar ratio of ferric trichloride, manganese dioxide and potassium dichromate is 1:9: 17.
The molar ratio of 3-chloro-2-methylaniline to di-tert-butyl dicarbonate is 1:1.3, the molar ratio of 3-chloro-2-methylaniline to manganese dioxide in the oxidant is 1:2.8, and the dosage ratio of 3-chloro-2-methylaniline to benzene, tetrahydrofuran and water is 1g:4mL:5mL:0.8 g.
The molar ratio of the 3-chloro-2-methylaniline to the hydrogen chloride in the hydrochloric acid is 1: 2; the volume ratio of the hydrochloric acid to the dioxane is 1: 2.5; the volume ratio of chloroform to dioxane is 1:3.
Example 2
The synthesis method of the 2-amino-6-chlorobenzoic acid comprises the following steps:
1) uniformly mixing 3-chloro-2-methylaniline, di-tert-butyl dicarbonate and chlorobenzene, and stirring and reacting at 40 ℃ for 1h to obtain a mixture I;
2) uniformly mixing an oxidant, water and tetrahydrofuran, introducing nitrogen, controlling the reaction temperature to be 145 ℃ and the reaction pressure to be 5 atmospheres to obtain a mixture II, dropwise adding the mixture I into the mixture II, controlling the dropwise adding time to be 50min, then controlling the temperature to be 160 ℃ and the reaction pressure to be 8 atmospheres, continuously reacting for 6h, and cooling to obtain a mixture III;
3) adding hydrochloric acid and dioxane with the mass fraction of 20% into the mixture III, controlling the reaction temperature to be 75 ℃, the reaction pressure to be normal pressure, reacting for 0.5h, and cooling to obtain a mixture IV;
4) and adding toluene into the mixture IV, standing for layering, washing an organic phase with water, drying with anhydrous magnesium sulfate, and concentrating and evaporating to remove the solvent by using a rotary evaporator to obtain a product. The molar yield was 97.8% and the GC purity 98.1%.
In the above step, the method for preparing the oxidizing agent: uniformly mixing ferric trichloride, newly prepared manganese dioxide and potassium dichromate, and activating for 30min at 150 ℃ by using a vacuum drying oven under the protection of argon gas to obtain the manganese dioxide-potassium dichromate; the molar ratio of ferric trichloride, manganese dioxide and potassium dichromate is 1:8: 16.
The molar ratio of 3-chloro-2-methylaniline to di-tert-butyl dicarbonate is 1:1.2, the molar ratio of 3-chloro-2-methylaniline to manganese dioxide in the oxidant is 1:2.1, and the dosage ratio of 3-chloro-2-methylaniline to chlorobenzene, tetrahydrofuran and water is 1g:3mL:4mL:0.5 g.
The molar ratio of the 3-chloro-2-methylaniline to the hydrogen chloride in the hydrochloric acid is 1: 1.6; the volume ratio of the hydrochloric acid to the dioxane is 1: 1.5; the volume ratio of toluene to dioxane was 1:2.
Example 3
The synthesis method of 2-amino-6-chlorobenzoic acid comprises the following steps:
1) uniformly mixing 3-chloro-2-methylaniline, di-tert-butyl dicarbonate and fluorobenzene, and stirring at 50 ℃ to react for 2h to obtain a mixture I;
2) uniformly mixing an oxidant, water and tetrahydrofuran, introducing argon, controlling the reaction temperature to be 155 ℃ and the reaction pressure to be 7 atmospheres to obtain a mixture II, dropwise adding the mixture I into the mixture II, controlling the dropwise adding time to be 70min, then controlling the temperature to be 175 ℃ and the reaction pressure to be 10 atmospheres, continuously reacting for 8 hours and cooling to obtain a mixture III;
3) adding hydrochloric acid and dioxane with the mass fraction of 20% into the mixture III, controlling the reaction temperature to be 90 ℃, the reaction pressure to be normal pressure, reacting for 1h, and cooling to obtain a mixture IV;
4) and adding chloroform into the mixture IV, standing for layering, washing an organic phase, drying by using a drying agent, and concentrating and evaporating by using a rotary evaporator to remove the solvent to obtain a product. The molar yield was 99.5% and the GC purity was 99.2%.
In the above steps, the method for preparing the oxidizing agent: uniformly mixing ferric trichloride, newly-prepared manganese dioxide and potassium dichromate, and activating for 60min at 180 ℃ by using a vacuum drying oven under the protection of argon gas to obtain the product; the molar ratio of ferric trichloride, manganese dioxide and potassium dichromate is 1:10: 18.
The molar ratio of 3-chloro-2-methylaniline to di-tert-butyl dicarbonate is 1:1.4, the molar ratio of 3-chloro-2-methylaniline to manganese dioxide in the oxidant is 1:3.2, and the dosage ratio of 3-chloro-2-methylaniline to fluorobenzene, tetrahydrofuran and water is 1g:5mL:6mL:1.2 g.
The molar ratio of the 3-chloro-2-methylaniline to the hydrogen chloride in the hydrochloric acid is 1: 2.2; the volume ratio of the hydrochloric acid to the dioxane is 1: 3; the volume ratio of chloroform to dioxane is 1: 4.
Example 4
The reaction pressure before the mixture I was added dropwise to the mixture II was set to 2 atmospheres, the reaction temperature was set to 100 ℃, and other reaction conditions and material use ratios were the same as in example 1, with a molar yield of 45.3% and a GC purity of 65.2%.
Example 5
The reaction pressure before the mixture I was added dropwise to the mixture II was set to 10 atmospheres, the reaction temperature was set to 170 ℃, and other reaction conditions and material use ratios were the same as in example 1, with a molar yield of 80.5% and a GC purity of 76.3%.
Example 6
The reaction pressure after the dropwise addition of the mixture I to the mixture II was set to 5 atm, the reaction temperature was set to 140 ℃ and the other reaction conditions and the material ratio were the same as in example 1, the molar yield was 68.6% and the GC purity was 71.5%.
Example 7
After the mixture I was added dropwise to the mixture II, the reaction pressure was set to 14 atmospheres, the reaction temperature was set to 200 ℃, the other reaction conditions and the material ratio were the same as in example 1, the molar yield was 83.2%, and the GC purity was 87.2%.
Example 8
Ferric trioxide in the oxidant was removed and only fresh manganese dioxide and potassium dichromate remained, and the other reaction conditions and material use ratios were the same as in example 1, with a molar yield of 42.3% and a GC purity of 55.2%.
Example 9
Fresh manganese dioxide in the oxidant was removed and only ferric trichloride and potassium dichromate remained, and other reaction conditions and material use ratios were the same as in example 1, with a molar yield of 72.3% and a GC purity of 67.1%.
Example 10
The potassium dichromate in the oxidant was removed and only ferric trichloride and fresh manganese dioxide were retained, and the other reaction conditions and material use ratios were the same as in example 1, and no target product was detected.
Example 11 product Structure analysis
Taking the product of example 1 as an example, the structural analysis data are as follows.
1) Melting point
169-161 ℃ and the reported value is 158-160 ℃.
2) Nuclear magnetic analysis
Hydrogen spectrum:1H-NMR (DMSO): δ 11.1(1H), δ 7.12(1H), δ 7.06(1H), δ 6.73(1H), δ 6.28 (2H). The various hydrogens are assigned to the product structure as follows:
and (4) performing nuclear magnetic analysis, wherein the structure of the product accords with that of a target substance, namely 2-amino-6-chlorobenzoic acid.
Claims (3)
1. The synthetic method of the laquinimod intermediate 2-amino-6-chlorobenzoic acid is characterized in that 3-chloro-2-methylaniline reacts under the action of a protective agent and an oxidant to obtain the 2-amino-6-chlorobenzoic acid, and the reaction process comprises the following steps:
1) uniformly mixing 3-chloro-2-methylaniline, a protective agent and a solvent S1, and stirring and reacting at 40-50 ℃ for 1-2 h to obtain a mixture I;
2) uniformly mixing an oxidant, water and a solvent S2, introducing protective gas, controlling the reaction temperature to 145-155 ℃ and the reaction pressure to 5-7 atmospheres to obtain a mixture II, dropwise adding the mixture I into the mixture II, controlling the dropwise adding time to be 50-70 min, then controlling the temperature to 160-175 ℃ and the reaction pressure to be 8-10 atmospheres, continuously reacting for 6-8 h, and cooling to obtain a mixture III;
3) adding hydrochloric acid and a solvent S3 into the mixture III, controlling the reaction temperature to be 75-90 ℃, controlling the reaction pressure to be normal pressure, reacting for 0.5-1 h, and cooling to obtain a mixture IV;
4) adding a solvent S4 into the mixture IV, standing for layering, washing an organic phase with water, drying a drying agent, and concentrating and evaporating to remove the solvent to obtain a product;
the preparation method of the oxidant comprises the following steps: uniformly mixing ferric trichloride, manganese dioxide and potassium dichromate, and activating at 150-180 ℃ for 30-60 min under the condition of isolating oxygen to obtain the product; the molar ratio of the ferric trichloride to the manganese dioxide to the potassium dichromate is 1 (8-10) to 16-18; the manganese dioxide is prepared newly;
the protective agent is di-tert-butyl dicarbonate, the solvent S1 is benzene, chlorobenzene or fluorobenzene, the solvent S2 is tetrahydrofuran, the solvent S3 is dioxane, the solvent S4 is toluene or chloroform, the protective gas is nitrogen or argon, and the drying agent is anhydrous sodium sulfate or anhydrous magnesium sulfate.
2. The method for synthesizing laquinimod intermediate 2-amino-6-chlorobenzoic acid according to claim 1, wherein the molar ratio of 3-chloro-2-methylaniline to di-tert-butyl dicarbonate is 1 (1.2-1.4), the molar ratio of 3-chloro-2-methylaniline to manganese dioxide in the oxidant is 1 (2.1-3.2), and the dosage ratio of 3-chloro-2-methylaniline to solvent S1, solvent S2 and water is 1g (3-5) mL (4-6) mL (0.5-1.2) g.
3. The method for synthesizing laquinimod intermediate 2-amino-6-chlorobenzoic acid according to claim 1, wherein the hydrochloric acid concentration is 20% by mass; the molar ratio of the 3-chloro-2-methylaniline to the hydrogen chloride in the hydrochloric acid is 1 (1.6-2.2); the volume ratio of the hydrochloric acid to the solvent S3 is 1 (1.5-3); the volume ratio of the solvent S4 to the solvent S3 is 1 (2-4).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910331199.9A CN110092727B (en) | 2019-04-24 | 2019-04-24 | Synthetic method of laquinimod intermediate 2-amino-6-chlorobenzoic acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910331199.9A CN110092727B (en) | 2019-04-24 | 2019-04-24 | Synthetic method of laquinimod intermediate 2-amino-6-chlorobenzoic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110092727A CN110092727A (en) | 2019-08-06 |
CN110092727B true CN110092727B (en) | 2022-07-08 |
Family
ID=67445641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910331199.9A Expired - Fee Related CN110092727B (en) | 2019-04-24 | 2019-04-24 | Synthetic method of laquinimod intermediate 2-amino-6-chlorobenzoic acid |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110092727B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1858040A (en) * | 2005-05-08 | 2006-11-08 | 中国科学院上海药物研究所 | 5,8-disubstituted quinazoline and its preparing method and use |
CN101926803A (en) * | 2009-06-23 | 2010-12-29 | 湘北威尔曼制药有限公司 | Application of quinazoline compounds |
CN101926802A (en) * | 2009-06-18 | 2010-12-29 | 湘北威尔曼制药有限公司 | Application of quinazoline compounds |
-
2019
- 2019-04-24 CN CN201910331199.9A patent/CN110092727B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1858040A (en) * | 2005-05-08 | 2006-11-08 | 中国科学院上海药物研究所 | 5,8-disubstituted quinazoline and its preparing method and use |
CN101926802A (en) * | 2009-06-18 | 2010-12-29 | 湘北威尔曼制药有限公司 | Application of quinazoline compounds |
CN101926803A (en) * | 2009-06-23 | 2010-12-29 | 湘北威尔曼制药有限公司 | Application of quinazoline compounds |
Non-Patent Citations (2)
Title |
---|
2-氯-6-氨基苯甲酸的合成;陈国广,瞿健;《化学试剂》;20071231;第29卷(第12期);第761-762页 * |
Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors;Yi Jin等;《Bioorganic & Medicinal Chemistry》;20050629;第13卷;第5613-5622页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110092727A (en) | 2019-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Eliel | Studies in asymmetric synthesis. Highly stereoselective reactions of organosulfur compounds | |
US11339174B2 (en) | γ-spiroketal-γ-lactones and pharmaceutical composition containing same and process for preparation thereof | |
CN114133350A (en) | Preparation method of anti-neocorolla drug Paxlovid intermediate | |
Bravo et al. | Asymmetric synthesis of α-arylglycinols via additions of lithium methyl p-tolyl sulfoxide to N-(PMP) arylaldimines followed by “non oxidative” Pummerer reaction | |
CN104017001B (en) | A kind of method of chemosynthesis mosictin | |
Qian et al. | Yb (OiPr) 3, A highly efficient catalyst for the nitro-mannich reaction | |
IE58851B1 (en) | Cholecalciferol derivatives and a process for their preparation | |
CN110092727B (en) | Synthetic method of laquinimod intermediate 2-amino-6-chlorobenzoic acid | |
CN101602656B (en) | Synthesis process for hinokitol | |
Montgomery et al. | Competition between insertion and conjugate addition in nickel-catalyzed couplings of enones with unsaturated functional groups | |
CN111592507A (en) | Novel green and simple method for preparing polysubstituted furan | |
CN113912577A (en) | Lockmilanol intermediate, Lockmilanol and derivatives thereof, preparation and application | |
CN109574913B (en) | Method for preparing geminal dinitro compound by nitrate hydrate | |
CN106631885A (en) | 4-formaldoxime benzoate derivative preparation method | |
CN106032381A (en) | Industrial production method of midazolam derivative | |
CN106032380A (en) | Industrial production method of midazolam | |
Turck et al. | Diazines. IX. Metalation of 2‐chloro, 2‐methoxy and 2‐pivaloylaminoquinoxaline | |
CN104788353B (en) | A kind of method for synthesizing 4 oxo L proline derivatives | |
CN109970649B (en) | Preparation method of 1, 2-dimethyl-3-phenylpyrazoline perchlorate | |
Guo et al. | A rapid entry into thioflavanones via conjugate additions of diarylcuprates to thiochromones | |
CN109134204A (en) | The synthetic method of the fluoro- 5- chlorophenol of the bromo- 4- of intermediate 2- | |
CN112939828A (en) | Beta-ketone sulfoxide derivative of carboxylic acid drugs and preparation method and application thereof | |
Bates et al. | Nucleophilic displacements on an. alpha.-chloro thioether by organocuprates: a novel synthesis of desoxybiotin | |
US3962053A (en) | Nitro group displacement | |
CN108840793B (en) | Method for preparing gamma-thujaplicin by using simulated moving bed chromatography |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220708 |